SMS Pharmaceuticals reported a strong performance for FY26, with net revenue rising 13% to Rs 887 crore and profit after tax climbing 47% to Rs 102 crore. The company declared a dividend of Re 0.40 per share while detailing a Rs 280 crore expansion plan. Investors should note an ongoing NCLT insolvency case involving a Rs 3.02 crore claim, which management is currently contesting.
SMS Pharmaceuticals Posts Strong FY26 Results
Net Revenue: Rs 887 Crore | PAT: Rs 102 Crore
Reader Takeaway: Strong operational growth and expansion plans are currently balanced by a pending NCLT insolvency dispute.
What just happened
SMS Pharmaceuticals released its consolidated financial results for FY 2025-26, reporting a 13% rise in net revenue to Rs 887 crore compared to the previous year. Profit after tax (PAT) saw a significant 47% increase, reaching Rs 102 crore, while EBITDA improved by 23% to Rs 171 crore. The Board has recommended a dividend of Re 0.40 per share, with a record date set for September 22, 2026.
Why this matters
The double-digit growth across all primary metrics signals strong operational efficiency. The company is investing Rs 280 crore in capex to boost its ibuprofen capacity to 9,600 MTPA, aiming to drive future revenue. The company also ramped up its regulatory footprint by filing 12 DMFs and CEPs this year, with 20 more planned over the next two years.
Risks to watch
Investors must monitor an NCLT insolvency petition filed by M/s. Sai Sreyas Pharmaceutical Pvt. Ltd. over an alleged debt of Rs 3.02 crore. The company has formally disputed the claim, citing defective supplies, and has filed a counter-rejoinder. The outcome of this legal proceeding remains a key point of uncertainty.
What to track next
Shareholders will vote on the re-appointment of Mr. Ramesh Babu Potluri as CMD for a five-year term at the upcoming AGM. Additionally, the execution speed of the Rs 280 crore capex program will be a critical indicator of the company's long-term growth trajectory.